GTX Medical was granted FDA Breakthrough Device Designation for Go-2 Targeted Epidural Spinal Stimulation (TESS) system9. June 2020|In Portfolio News|By eazee-designstudioThe US Food and Drug Administration has granted Breakthrough Device Designation for GTX Medical‘s implantable Go-2 system which was designed to promote the recovery of leg motor functions and neurological control in adults with spinal cord injuries (SCI) and paralysis. The Go-2 System provides Targeted Epidural Spinal Stimulation (TESS) therapy, promoting the recovery of leg motor functions and neurological control. The Company anticipates the first clinical trial for the complete Go-2 system in humans to take place in 2021. PrevNext
